Login to Your Account

Elan, Proteostasis Join Forces in Early Stage Collaboration

By Catherine Shaffer

Thursday, May 26, 2011
Elan Corp. has committed as much as $50 million in a new approach to neurodegenerative disease being pioneered by Cambridge, Mass.-based Proteostasis Therapeutics Inc. The alliance will make use of Proteostasis assets and expertise in protein folding to identify and advance molecular entities that prevent misfolding of protein.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription